Molecule discovery could be used to treat rheumatoid arthritis

A new molecule has been found by a pharmaceutical company that could in the future be used to treat diseases such as rheumatoid arthritis and inflammatory bowel disease.

GBR 830 is an anti-OX40 monoclonal antibody (OX40 is responsible for some autoimmune diseases). It seems that it is one of a kind; Dr Michael Buschle from Glenmark Pharmaceuticals says there are currently no antagonistic antibodies targeting OX40 in the clinical stage of development.

“We are confident that the antibody expertise and product development capabilities of the Switzerland Biologics Research Centre will continue to enrich the Glenmark discovery pipeline,” he comments.

Studies have begun for the investigational new drug application to be filed with the US Food and Drug Administration.